Disease-a-month : DM
-
Disease-a-month : DM · Sep 2020
ReviewCOVID-19 extrapulmonary illness - special gastrointestinal and hepatic considerations.
Coronaviruses have caused three global outbreaks in the last 20 years, which include Severe Acute Respiratory Syndrome (SARS) caused by SARS-CoV (SARS-CoV-1), Middle East Respiratory Syndrome (MERS) by MERS-CoV and Coronavirus Disease-2019 (COVID-19) due to SARS-CoV-2. These outbreaks share many similarities, including clinical presentation, transmission, and management. Although respiratory manifestations are responsible for most of the morbidity and mortality in these conditions, extra-pulmonary manifestations such as gastrointestinal symptoms are also increasingly recognized as important symptoms. ⋯ Though GI symptoms are frequently observed, understanding the pathogenesis of these symptoms is crucial, as it can not only of public health importance but could also identify infected patients early in the spread. Understanding the different GI and hepatic manifestations with underlying mechanisms of symptoms can assist in the therapeutic management of these patients. In this article, we summarize various GI and hepatic manifestations with their prevalence, underlying pathophysiology with emphasis on stool positivity.
-
Disease-a-month : DM · Sep 2020
ReviewCOVID-19 Extrapulmonary illness - The Impact of COVID-19 on Nephrology care.
Coronavirus disease-2019 (COVID-19) has caused a pandemic that has affected millions of people worldwide. COVID-19 is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and is spread by close contact and by respiratory droplets. ⋯ All of these patients are considered high risk. The lessons learned from the COVID-19 pandemic will hopefully serve to protect patients with kidney disease in a similar situation in the future.
-
Disease-a-month : DM · Sep 2020
ReviewCOVID-19: Therapeutics and interventions currently under consideration.
With the emergence of COVID-19 extensive research began to identify medications, candidate compounds and other therapeutic approaches. The complex virology of COVID-19 may provide multiple potential target points for antiviral therapy, and vaccines; extensive global research is underway to exploit these potential opportunities. The complex pathophysiology, pulmonary and extrapulmonary disease, and immune mediated effects such as cytokine storm, make medical management more challenging than many viral illnesses. ⋯ Although a comprehensive look at various classes of interventions, it is by no means a complete list of every compound trialed against COVID-19. Recognizing the knowledge basis upon which we treat COVID-19 patients, develop therapeutics, and vaccines continues to evolve as new information is presented, every effort nevertheless has been made to provide as timely information as possible. It is hoped that the information shared can help guide the clinician in terms of potential options to treat this complex group of patients.
-
Disease-a-month : DM · Sep 2020
Review Comparative StudyMiddle East Respiratory Syndrome (MERS) Coronavirus.